|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study显示文摘 | Patrick Marcellin Edward Gane Maria Buti Nezam Afdhal William Sievert Ira M Jacobson Mary Kay Washington George Germanidis John F Flaherty Raul Aguilar Schall Jeffrey D Bornstein Kathryn M Kitrinos G Mani Subramanian John G McHutchison E Jenny Heathcote | 2012 | The Lancet2012，，： | 14 |
| 2 | The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research显示文摘 | Edwin J. Lai Audrey H. Calderwood Gheorghe Doros Oren K. Fix Brian C. Jacobson | 2009 | Gastrointestinal Endoscopy2009，，3： | 10 |
| 3 | STEM教育视域下虚拟学习环境Omosa项目分析及应用启示显示文摘Omosa是澳大利亚悉尼大学基于STEM理念开发的虚拟学习环境,模拟星球生态系统关系,用于培养学生的知识建构与创新能力。利用模型构建的方法分析了Omosa虚拟学习环境的内部结构模型和外部结构特征,其学习者模块、环境模块、代理模块、事件模块和干预模块协调有序地配合,构筑了浸润式的类似于真实的学习环境,使学生在参与科学探究过程中有意义地建构科学、工程等学科知识。基于Omosa三维环境和二维环境的实现机制、个体代理推理机制和算法机制,实现了一个开放的、复杂的和适应性的智能学习环境,学生可主动地探索虚拟世界中事物之间的关系,寻求解决问题的策略,使学习转变为一个意义建构的生态过程。以Netlogo环境为例,设计了教师教和学生学的双重过程模型,基于5E学习循环模型开展项目活动,通过学习效能量表调查发现学生在自我效能、动机、元认知意识、技能等方面均有提升。此外,虚拟学习环境的认知工具和可视化学习工具及学习资源帮助学生提升了问题解决能力,促进了学习者计算性思维和高阶思维的发展,有助于MOOC学习和创客教育。 | 韩建华 姜强 赵蔚 Michael J. Jacobson | 2016 | 中国电化教育2016，，12： | 8 |
| 4 | 植物质杀虫剂的过去、现在和未来显示文摘过去,西方各国使用的植物质杀虫剂还只是除虫菊、鱼藤酮、尼古丁、沙巴草和苦木素。现在鱼藤酮因其对鱼的高毒性只用于有限的一些农作物。出自菊花的天然除虫菊对侵害人、畜的有害昆虫主要作为一种快速击倒剂。尼古丁、沙巴革和苦木至今已很少作为杀虫剂使用。作者基于44年来对许多科的数千种植物用作杀虫剂的研究,认为现在和将来最有应用前途的植物质杀虫剂是下列科目的植物:楝科、芸香科、紫菀科、锦葵科、唇形科以及 Cancllaccae。 | Martin Jacobson 薛建平 | 1993 | 国外农学(植物保护)1993，6，2： | 7 |
| 5 | Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus显示文摘 | Alexander J. Thompson Andrew J. Muir Mark S. Sulkowski Dongliang Ge Jacques Fellay Kevin V. Shianna Thomas Urban Nezam H. Afdhal Ira M. Jacobson Rafael Esteban Fred Poordad Eric J. Lawitz Jonathan McCone Mitchell L. Shiffman Greg W. Galler William M. Lee | 2010 | Gastroenterology2010，，1： | 7 |
| 6 | Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection显示文摘 | Nezam Afdhal Stefan Zeuzem Paul Kwo Mario Chojkier Norman Gitlin Massimo Puoti Manuel Romero-Gomez Jean-Pierre Zarski Kosh Agarwal Peter Buggisch Graham R. Foster Norbert Br?u Maria Buti Ira M. Jacobson G. Mani Subramanian Xiao Ding Hongmei Mo Jenny C. Ya | 2014 | The New England Journal of Medicine2014，，： | 6 |
| 7 | 板坯结晶器流场控制的发展趋势显示文摘鉴于电磁装置在提高板坯质量方面得到了普遍的认可,因此,过去几年大家对它的关注与日俱增。通过电磁装置对结晶器内钢液进行搅拌和/或者制动作用,能大大提高板坯的表面和皮下质量。不同的浇铸条件,如拉速和铸坯断面尺寸等与铸坯质量密切相关,而恰当地利用电磁技术可最大限度取得最好的产品质量。在低通钢量时通常需要搅拌(AC)功能,而大通钢量时则需要制动功能(DC)。这种具有挑战性的电磁装置已经被开发出来,其特点是功能多样化和操作灵活性,可通过对结晶器整个宽面的流场控制来最大限度地提高板坯质量。 | 钟云涛 潘汉玉 Nils Jacobson Martin Seden | 2016 | 宝钢技术2016，9，4： | 6 |
| 8 | 前庭诱发肌源性电位记录的当代热点显示文摘专家简介:GaryP.Jacobson,哲学博士,范德堡大学医学中心范德堡·比尔·威尔克森中心听力学部主任,《美国听力学杂志》(美国言语一语言听力学会)前编辑,《美国听力学会杂志》现任主编,著有或合作著有超过140篇同行评议论著和专著章节,涵盖范围包括耳鸣、眩晕、听觉功能、结果测量发展、脑图和术中神经生理学。《平衡功能检查手册》、《平衡功能评价与治疗》的合作编者,近来为美国言语语言听力协会会员,因听力学研究获Jerger职业奖(2002),美国听力学会授予其杰出成就奖(2015),2010年获美国言语一语言听力协会授予的协会荣誉。 | Jacobson G P McCaslin D L 刘波(译) 张华(审校) | 2016 | 临床耳鼻咽喉头颈外科杂志2016，30，23： | 5 |
| 9 | A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update显示文摘 | Emmet B. Keeffe Douglas T. Dieterich Steven-Huy B. Han Ira M. Jacobson Paul Martin Eugene R. Schiff Hillel Tobias | 2008 | Clinical Gastroenterology and Hepatology2008，，12： | 5 |
| 10 | Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir显示文摘 | Fred Poordad Jean–Pierre Bronowicki Stuart C. Gordon Stefan Zeuzem Ira M. Jacobson Mark S. Sulkowski Thierry Poynard Timothy R. Morgan Cliona Molony Lisa D. Pedicone Heather L. Sings Margaret H. Burroughs Vilma Sniukiene Navdeep Boparai Venkata S. Goteti | 2012 | Gastroenterology2012，，3： | 5 |
| 11 | Quality indicators for colonoscopy显示文摘 | Douglas K. Rex John L. Petrini Todd H. Baron Amitabh Chak Jonathan Cohen Stephen E. Deal Brenda Hoffman Brian C. Jacobson Klaus Mergener Bret T. Petersen Michael A. Safdi Douglas O. Faigel Irving M. Pike | 2006 | Gastrointestinal Endoscopy2006，，4： | 4 |
| 12 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 3 |
| 13 | Random Early Detection Gateways for Congestion Avoidance显示文摘 | Floyd S Jacobson V | | 0，，： | 3 |
| 14 | A lexicon for endoscopic adverse events: report of an ASGE workshop显示文摘 | Peter B. Cotton Glenn M. Eisen Lars Aabakken Todd H. Baron Matt M. Hutter Brian C. Jacobson Klaus Mergener Albert Nemcek Bret T. Petersen John L. Petrini Irving M. Pike Linda Rabeneck Joseph Romagnuolo John J. Vargo | 2010 | Gastrointestinal Endoscopy2010，，3： | 3 |
| 15 | Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients显示文摘BACKGROUND Asymptomatic children with Crohn's disease(CD) require ongoing monitoring to ensure early recognition of a disease exacerbation.AIM In a cohort of pediatric CD patients, we aimed to assess the utility of serial fecal calprotectin measurements to detect intestinal inflammatory activity and predict disease relapse.METHODS In this prospective longitudinal cohort study, children with CD on infliximab therapy in clinical remission were included. Fecal calprotectin levels were assessed at baseline and at subsequent 2-5 visits. Clinical and biochemical disease activity were assessed using the Pediatric Crohn's Disease Activity Index, Creactive protein and erythrocyte sedimentation rate at baseline and at visits over the following 18 mo.RESULTS 53 children were included and eighteen patients(34%) had a clinical disease relapse during the study. Baseline fecal calprotectin levels were higher in patients that developed symptomatic relapse [median(interquartile range), relapse 723μg/g(283-1758) vs 244 μg/g(61-627), P = 0.02]. Fecal calprotectin levels > 250μg/g demonstrated good predictive accuracy of a clinical flare within 3 mo(area under the receiver operator curve was 0.86, 95% confidence limits 0.781 to 0.937).CONCLUSION Routine fecal calprotectin testing in children with CD in clinical remission is useful to predict relapse. Levels > 250 μg/g are a good predictor of relapse in the following 3 mo. This information is important to guide monitoring standards used in this population. | Alice Jane Foster Matthew Smyth Alam Lakhani Benjamin Jung Rollin F Brant Kevan Jacobson | 2019 | World Journal of Gastroenterology2019，25，10： | 3 |
| 16 | A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update显示文摘 | Emmet B. Keeffe Douglas T. Dieterich Steven–Huy B. Han Ira M. Jacobson Paul Martin Eugene R. Schiff Hillel Tobias Teresa L. Wright | 2006 | Clinical Gastroenterology and Hepatology2006，，8： | 2 |
| 17 | Oxidation microstructure studies of reinforced carbon/carbon显示文摘 | Nathan S. Jacobson Donald M. Curry | 2005 | Carbon2005，，7： | 2 |
| 18 | Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants显示文摘 | George K. Siberry Paige L. Williams Hermann Mendez George R. Seage Denise L. Jacobson Rohan Hazra Kenneth C. Rich Raymond Griner Katherine Tassiopoulos Deborah Kacanek Lynne M. Mofenson Tracie Miller Linda A. DiMeglio D. Heather Watts | 2012 | AIDS2012，，9： | 2 |
| 19 | Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis显示文摘AIM To confirm previous conclusions on Saccharomyces cerevisiae(S. cerevisiae) CNCM I-3856 for irritable bowel syndrome(IBS) management.METHODS An individual patient data meta-analysis was performed on two randomized clinical trials studying the effect of S. cerevisiae CNCM I-3856 supplementation on gastrointestinal(GI) symptoms in IBS subjects. A total of 579 IBS subjects were included. Outcomes were the daily Likert scale scores of abdominal pain/discomfort and bloating [area under the curve(AUC) and weekly means], responder status, and bowel movements(stool frequency and consistency). Statistical analyses were conducted in Intent to Treat(ITT) population, IBS-C subjects and IBS-C subjects with an abdominal pain/discomfort score higher than or equal to 2 at baseline('IBS-C ≥ 2 subpopulation').RESULTS S. cerevisiae CNCM I-3856 significantly improved abdominal pain/discomfort and bloating during the second month of supplementation [AUC(W5-W8)]with improvement up to the minimal clinically relevant threshold of 10%: a 12.3% reduction of abdominal pain/discomfort in the ITT population compared to the Placebo group(P = 0.0134) has been observed. In the IBS-C ≥ 2 subpopulation, there were a 13.1% reduction of abdominal pain/discomfort and a 14.9% reduction of bloating compared to the Placebo group(P = 0.0194 and P = 0.0145, respectively). GI symptoms significantly decreased during supplementation but no statistical differences were reported between groups at the end of the supplementation period. Responder status was defined as a subject who experienced a decrease of 1 arbitrary unit(a.u.) or 50% of the abdominal discomfort score from baseline for at least 2 wk out of the last 4 wk of the study. A significant difference between groups was reported in the ITT population, when considering the first definition: subjects in the Active group had 1.510 higher odds to be a responder(reduction of 1 a.u. of abdominal pain/discomfort) compared with subjects in the Placebo group(P = 0.0240). At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as 'normal' compared to Placebo(respectively 3.13 ± 1.197 a.u. vs 2.58 ± 1.020 a.u., P = 0.0003). Similar results were seen in the IBS-C ≥ 2 subpopulation(Active group: 3.14 ± 1.219 a.u. vs Placebo group: 2.59 ± 1.017 a.u., P = 0.0009).CONCLUSION This meta-analysis supports previous data linking S. cerevisiae I-3856 and improvement of GI symptoms, in IBS overall population and in the IBS-C and IBS-C ≥ 2 subpopulations. | Amélie Cayzeele-Decherf Fanny Pélerin Sébastien Leuillet Benoit Douillard Béatrice Housez Murielle Cazaubiel Gunnard K Jacobson Peter Jüsten Pierre Desreumaux | 2017 | World Journal of Gastroenterology2017，23，2： | 2 |
| 20 | Transition clinic attendance is associated with improved beliefs and attitudes toward medicine in patients with inflammatory bowel disease显示文摘AIM To evaluated the differences in knowledge, adherence, attitudes, and beliefs about medicine in adolescents with inflammatory bowel disease(IBD) attending transition clinics.METHODS We prospectively enrolled patients from July 2012 to June 2013. All adolescents who attended a tertiarycentre-based dedicated IBD transition clinic were invited to participate. Adolescent controls were recruited from university-affiliated gastroenterology offices. Participants completed questionnaires about their disease and reported adherence to prescribed therapy. Beliefs in Medicine Questionnaire was used to evaluate patients' attitudes and beliefs. Beliefs of medication overuse, harm, necessity and concerns were rated on a Likert scale. Based on necessity and concern ratings, attitudes were then characterized as accepting, ambivalent, skeptical and indifferent. RESULTS One hundred and twelve adolescents were included and 59 attended transition clinics. Self-reported adherence rates were poor, with only 67.4% and 56.8% of patients on any IBD medication were adherent in the transition and control groups, respectively. Adolescents in the transition cohort held significantly stronger beliefs that medications were necessary(P = 0.0035). Approximately 20% of adolescents in both cohorts had accepting attitudes toward their prescribed medicine. However, compared to the control group, adolescents in the transition cohort were less skeptical of(6.8% vs 20.8%) and more ambivalent(61% vs 34%)(OR = 0.15; 95%CI: 0.03-0.75; P = 0.02) to treatment.CONCLUSION Attendance at dedicated transition clinics was associated with differences in attitudes in adolescents with IBD. | Nancy Fu Kevan Jacobson Andrew Round Kathi Evans Hong Qian Brian Bressler | 2017 | World Journal of Gastroenterology2017，23，29： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员